**Glycometabolism change during *Burkholderia pseudomallei* infection in RAW264.7 cells by proteomic analysis**

Xuexia Li, Yingfei Zeng, Shengnan Guo, Chen Chen, Lin Liu & Qianfeng Xia*

*Burkholderia pseudomallei* is a Gram-negative intracellular bacterium that causes melioidosis, a life-threatening disease. The interaction of *B. pseudomallei* with its host is complicated, and cellular response to *B. pseudomallei* infection is still largely unknown. In this study, we aimed to determine host-cell responses to *B. pseudomallei* at the proteomics level. We performed proteomic profiling of *B. pseudomallei* HNBP001-infected mouse macrophage RAW264.7 cells to characterize the cellular response dynamics during infection. Western blot analysis was utilized for the validation of changes in protein expression. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted using the clusterProfiler R package. Compared with the negative control (NC) group, 811 common proteins varied over time, with a cut-off level of two fold change and an adjusted *P*-value less than 0.05. The bioinformatics analysis revealed that the proteins significantly changed in the *B. pseudomallei* HNBP001 infection group (*Bp* group) were enriched in glycometabolism pathways, including glycolysis, fructose and mannose metabolism, pentose phosphate pathway, galactose metabolism, and carbon metabolism. Western blot analysis verified three selected proteins involved in glycometabolism pathways, namely PGM1, PKM, and PGK1 were increase over time post the infection. Furthermore, in vitro functional analysis revealed an increased glucose uptake and decreased ATP production and O-GlcNAcylation in the *Bp* group compared with control group, suggesting that *B. pseudomallei* HNBP001 infection induces changes in glycometabolism in RAW264.7 cells. These results indicate that glycometabolism pathways change in RAW264.7 cells post *B. pseudomallei* HNBP001 infection, providing important insights into the intimate interaction between *B. pseudomallei* and macrophages.

**Key Laboratory of Tropical Translational Medicine of Ministry of Education, NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine and The Second Affiliated Hospital, Hainan Medical University, Haikou 571199, Hainan, China.**

**email:** xiaqianfeng@hainmc.edu.cn
interrelationships, such as enriched biological processes and pathways, will provide insight into the combined influence of *B. pseudomallei* on body function. There have been some studies explored the interaction between hosts and *B. pseudomallei*\(^{22-24}\). For example, Loaiza et al. predicted host-pathogen protein interactions in *B. pseudomallei* and human in silico, discovered the host targets of the pathogen proteins and proteins that form T3SS and T6SS in *B. pseudomallei*. Schmidt et al. found that *B. pseudomallei* modulated host iron homeostasis to facilitate intracellular survival.

Given that RAW264.7 cells have been widely used for modeling *B. pseudomallei* in vitro\(^{16-18}\), in this study we aimed to establish the *B. pseudomallei* HNBP001 infection model of RAW264.7 cells (*Bp*) and utilize this model to investigate the host-cell responses. For this purpose, we performed high-resolution liquid chromatography-tandem MS (LC–MS/MS) in the *Bp* group and negative control (NC) group\(^{19}\). Our results demonstrate that a large number of proteins in host cells are altered significantly after infection with *B. pseudomallei* HNBP001, which might provide a new direction for future work to reveal the pathogenic mechanism of *B. pseudomallei* in macrophages.

**Results**

**RAW264.7 cell *B. pseudomallei* HNBP001 infection model.** To establish an in vitro *B. pseudomallei* HNBP001 infection model, we infected RAW264.7 cells with *B. pseudomallei* HNBP001 at different MOIs or time-points following the protocol described in a previous study\(^{20}\). We determined the cell morphology under a microscope and noted cell viability decreasing with the duration of infection (Fig. 1A). As shown in Fig. 1B, at 6 h post-infection, *B. pseudomallei* HNBP001 induced 50% MNGC (multinuclear giant cell) formation, with 80% MNGC formation at 12 h post-infection, and 95% MNGC formation at 24 h post-infection, where almost all the cells died at this time. We adapted the cell fusion assay shown in Fig. 1C for screening by seeding RAW264.7 cells into a 10 cm dish, infecting cells with *B. pseudomallei* HNBP001, then staining them with Giemsa and imaging them using a microscope to assess the relative abundance and size of plaques (Fig. 1D). According to the results, the RAW264.7 cell *B. pseudomallei* infection model was established successfully.

When infected with *B. pseudomallei* HNBP001 MOI 50 for 12 h, the cell viability decreased 40%, MNGCs increased nearly 80%, and the plaque area increased 2.5-fold, suggesting that the proteins in RAW264.7 cells have changed. Thus RAW264.7 cells infected with *B. pseudomallei* HNBP001 MOI 50 for 12 h (*Bp* group), and matching RAW264.7 cells (NC group), were subjected to proteome profiling analysis.

**Proteome profiling of *B. pseudomallei* HNBP001 infected RAW264.7 cells.** To determine the proteome profiling, we employed a LC–MS/MS for proteome profiling and digested extracted proteins from cells with trypsin. The resulting peptides were labeled with TMT/iTRAQ and analysed on QE Plus mass spectrometer. The LC–MS/MS platform was stable and repeatable, as judged by quality control runs during the overall data-collecting period (Supplementary Fig. 1).

We analyzed the raw files together for uniformed quality control, and adjusted protein identification with P-values using the Holm method\(^{27}\). In total, we identified a total of 6671 proteins and quantified 5924 proteins by the LC–MS/MS. A SAM (significance analysis of microarray)\(^{28}\) analysis identified 811 proteins as differentially expressed between *Bp* group and NC group, with statistical significance (Holm adjust *P* < 0.05, Fold Change > 2 or < 0.5) (Fig. 2A, Supplementary Table 1). As shown in Fig. 2B, many proteins were annotated as the intracellular matrix, and 50% of proteins were located in the nucleus, suggesting that our proteome dataset includes the cellular metabolism.

The Gene Ontology annotation indicated that the up-regulated proteins were significantly enriched in ribonucleoprotein complex biogenesis, ribosome biogenesis, tRNA processing, and miRNA processing (Fig. 2C, Supplementary Table 2). The KEGG GSEA enrichment analysis showed that purine metabolism, carbon metabolism, pentose phosphate pathway, fructose and mannose metabolism, and glycolysis pathways were significantly enriched (Fig. 2D, Supplementary Table 3).

**Change of proteins involved in glycometabolism pathways.** We next characterized those differentially expressed proteins which are involved in glycometabolism pathways, including those involved in glycolysis (-LDHA, PGM2, PKM, PGMI-), carbon metabolism (-ADH5, GOT1, PGK1, G6PDH-), pentose phosphate pathway (-ALDOA, PGLS, TALDO1-), fructose and mannose metabolism (-PGLS, TALDO1-), and galactose metabolism (-AKR1B7, AKR1B1, UGP2, GALK1-). As summarized in Table 1, all those proteins were up-regulated in the *Bp* group, suggesting that the glycometabolism of host cells changed while being infected with *B. pseudomallei* HNBP001.

To validate the proteome changes, we selected three enzymes in the glycolysis and carbon metabolism pathway—PGM1, PKM, and PGK1—for verification using the Western Blot. As expected, the expression levels of PGM1, PKM, and PGK1 in the *Bp* group were increased about 3.02-fold, 9.45-fold, and 3.5-fold respectively.

**Correlation of *B. pseudomallei* HNBP001 model proteomes with glycometabolism.** The elevated expression of PGM1, PKM, and PGK1 accelerate the glycolysis pathway\(^{22-24}\); thus, we speculated that the *B. pseudomallei* HNBP001 infection accelerated glucose uptake in host cells. As expected, the *Bp* group takes more glucose compared with the NC group (Fig. 4A). We then detected ATP production in the NC and *Bp* group, and the production of ATP was significantly reduced in the *Bp* group (Fig. 4B). Glucose also is a substrate of O-GlcNAcylation, a post-translation modification. Therefore, we further examined the level of O-GlcNAcylation in the NC and *Bp* groups. The results showed that the level of O-GlcNAcylation was significantly decreased.
Figure 1. RAW264.7 cell B. pseudomallei HNBP001 infection model. (A) RAW264.7 cells were infected with B. pseudomallei HNBP001 MOI 50 at 0, 1, 3, 6, 12, or 24 h; cell morphology was observed under the microscope; and quantification of cell viability was indicated. (B) RAW264.7 cells were stained with Giemsa, and MNGCs were counted. Quantification of MNGCs was indicated. Mononuclear means the number of cells only with one nucleus, binucleus means the number of cells with two nuclei, trinucleus means the number of cells with three nucleus, and the multinucleus means the number of cells with more than three nucleus. (C) Cell fusion assay with example well images show RAW264.7 cell monolayers infected with B. pseudomallei HNBP001 and stained with Giemsa. (D) The relative abundance and size of plaques while infected with B. pseudomallei HNBP001 was assessed at different MOI or times. We conducted the same experiment three times independently.
in the Bp group (Fig. 4C), suggesting that B. pseudomallei HNB001 strictly regulates the glucose metabolism of host cells.

Discussion
Melioidosis is an infectious disease caused by the Gram-negative bacteria B. pseudomallei. Elucidating the cellular response to B. pseudomallei infection will aid in unraveling the pathogenic mechanisms of the pathogen, and most cellular responses to pathogens involve alterations in protein expression. Thus, we explored host-cell responses to B. pseudomallei at the proteomics level in this study. In an earlier study26, B. pseudomallei infection induced hosts’ membrane fusion, and multiple cell fusion events resulted in the formation of large multinucleate cells, which eventually lyse to form lesions on cell monolayers. It was consistent with the RAW264.7 cell B. pseudomallei HNB001 infection model established by us, and this model is subjected to proteomic analysis successfully.

LC–MS/MS was performed in our study, and we identified 811 proteins when the P-values were adjusted using the Holm method. Additionally, 275 proteins increased more than three-fold and 123 proteins decreased more than three-fold in B. pseudomallei HNB001 infected RAW264.7 cells. The bioinformatics analysis showed that many proteins involved in glycometabolism are changed when infected with B. pseudomallei HNB001, which contain proteins involved in glycolysis, carbon metabolism, galactose metabolism, pentose phosphate pathway, and the fructose and mannose metabolism pathway. In early study, Welkos et al.27 have identified 160 B. pseudomallei’s proteins in the infected RAW 264.7 cells, and 274 host proteins that were exclusively present or absent in infected cells. However, they focused on B. pseudomallei’s proteins, constructed mutation genes and assessed their relative virulence. There is a lack of information on the detailed functions of host proteins and relative signaling pathways in their study. Similarly, Mariappan et al.20 have identified 44 up regulated and 43 down regulated proteins in A549 cells infected with BpMARAN, which related to metabolism, stress response, virulence, signal transduction, or adhesion. Their study targeted to lung cells, however, B. pseudomallei usually attacks the host’s immune system first, then causing lesions in organs4. Thus, it is more relevant to explore the changes of proteins in macrophages, which can contribute to the study of the infection mechanism of B. pseudomallei. To our knowledge, the present study for the first time shows that melioidosis is associated with glycometabolism in immune cells. Additionally, our results provided a platform for the protein expression library of RAW264.7 cells infected with B. pseudomallei HNB001, and deciphering the alterations of proteomic profiling provides insight into the response mechanism of hosts.

Alterations in the expression of proteins involved in glycometabolism can lead to glycometabolism abnormally, as well as diseases. For example, high PGK1 expression resulted in the promotion of glycolysis, enhancing the stem cell-like properties and EMT by activating AKT signaling in oral squamous cell carcinoma cells28. High expression of ALDOA is also related to galactose metabolism and colorectal cancer, lung cancer, and gastric cancer29–31. Additionally, PKM activation increases glucose metabolic flux, inhibiting the production of toxic glucose metabolites in diabetics32. These changes increase glucose uptake because most substrates of glycometabolism are derived from glucose33, this is consistent with our results.

Unexpectedly, the production of ATP was lower in the Bp group. Mitochondria, as the main cellular organ producing ATP, could be damaged due to bacterial toxicity in the Bp group34. B. pseudomallei produce bongkrekic acid (BA) in the host cell during the infection stage, and BA is toxic to the mitochondrial of host cells by inhibiting adenine nucleotide translocase35. Which resulted in a significant decrease in ATP production in Bp group, but glucose was taken up to help the adhesion and invasion of B. pseudomallei HNB00136.
There is a strong correlation between diabetes mellitus and *B. pseudomallei* infection, as 23–60% of patients with melioidosis also have diabetes\(^3\). But it is currently unknown why are people with diabetes are more susceptible to *B. pseudomallei*\(^3\). A previous study showed that diabetes results in blunted *B. pseudomallei*-specific cellular responses during acute infection\(^3\) and possibly due to glucose affecting the thioester bond of neutrophils complement C3 and thereby preventing binding to the bacterial surface\(^3\). Another study showed that glucose significantly increased adherence and invasion of *B. pseudomallei* to A549 cells\(^3\), but the mechanism is still unclear. Here, we present a new potential mechanism: abnormal glucose metabolism leads to O-GlcNAc modification abnormally; O-GlcNAcylation may affect the ability of host cells to respond to *B. pseudomallei* through regulating the function and structure of host cell proteins.

O-GlcNAcylation is a posttranslational modification of serine and/or threonine residues of nuclear and cytosolic proteins. Glucose in cells can enter the hexosamine synthesis pathway which converts glucose to uridine-5'-diphosphate-N-acetylglucosamine (UDP-GlcNAc), as the substrate for O-GlcNAcylation. Increasing evidence has shown that O-GlcNAcylation regulates various important biological processes, including transcription, stem-cell differentiation, signal transduction, cell cycle progression, and metabolic reprogramming via regulating the function of proteins\(^4\),\(^5\). Aberrant O-GlcNAcylation on various protein substrates has been implicated in many diseases, including cancers\(^6\), neurodegenerative diseases\(^7\), diabetes\(^8\), and immune diseases\(^9\). The O-GlcNAcylation level was decreased in *B. pseudomallei* HNBP001 infected RAW264.7 cells in our study.

**Figure 2.** Proteome profiling of *B. pseudomallei* HNBP001 infected RAW264.7 cells. (A) Volcano plot of 811 differential expressed proteins. The Log2-transformed fold change and –log 10-transformed adjusted P-value were denoted by the x-axis and y-axis, respectively. (B) Subcellular distribution of proteins was annotated with Gene Ontology. Many proteins were annotated as the intracellular matrix, and 50% of proteins were located in the nucleus. (C) The Biological Processes altered in the Bp group compared with the NC group. The top 20 significantly altered terms of up-regulated and down-regulated proteins were depicted in the picture. (D) The ridgeline plot for expression distribution of core-enriched proteins in KEGG categories, where the x-axis represented Log2-transformed fold change.
which verified that O-GlcNAcylation was associated with melioidosis for the first time. However, the proteins and mechanisms that O-GlcNAcylation regulates in melioidosis warrant further investigation in the future. As an extension of this study, it would be intriguing to investigate the molecular mechanism by which glycometabolism signal pathway is regulated in host cells by *B. pseudomallei* HNBP001.

**Conclusion**

Herein, we provide proteomic profiling of *B. pseudomallei* HNBP001-infected mouse macrophage RAW264.7 cells to characterize the cellular response dynamics during infection. The results in this study indicated that glycometabolism changed during *B. pseudomallei* HNBP001 infection, and they provide important insights into the intimate interaction between *B. pseudomallei* and macrophages, which can be further explored to elucidate the cellular mechanisms of *B. pseudomallei* infections.

**Materials and methods**

**Bacterial strains, cell lines, and culture conditions.** *B. pseudomallei* HNBP001 was isolated from the serum of a melioidosis patient with pneumonia in Hainan and cultured it using Luria–Bertani (LB) broth, according to the protocols earlier described. Bacterial growth curve and viable counts were performed, according to Mariappan et al., in three independent experiments. In brief, *B. pseudomallei* HNBP001 was cultured in LB liquid medium (GM+) at 37 °C, 220 rpm for about 18 h, until the OD reached 0.88. All the experiments of *B. pseudomallei* HNBP001 were performed in P3 laboratory. Mouse macrophages cell line RAW264.7 cell was obtained from ATCC and cultured with DMEM medium (10% FBS), 5%CO2 at 37 °C.

**Cell infection of *B. pseudomallei* HNBP001.** RAW264.7 cells were cultured in 6 well plate (1.2 × 10^6 per-well) for 24 h and challenged them via the infected with MOI (multiplicity of infection: the number of *B. pseudomallei* / the number of RAW264.7 cells) 0, 0.5, 1, 10, 20 or 50 of *B. pseudomallei* HNBP001 for 1, 3, 6, 12,

| Gene name | Express ratio (*Bp* group/*NC* group) | *P* value | FDR | Involved in signaling pathway |
|-----------|--------------------------------------|-----------|-----|-----------------------------|
| LDHA      | 5.385                                | 2.64E−07  | 0.001462986 | glycolysis                  |
| PGM2      | 5.377                                | 1.55E−09  | 8.71E−06   | carbon metabolism           |
| PKM       | 3.923                                | 4.17E−06  | 0.021022669|                           |
| PGM1      | 6.486                                | 5.40E−07  | 0.002948511|                           |
| ADH5      | 3.084                                | 3.17E−06  | 0.016275224|                           |
| GOT1      | 4.225                                | 8.19E−07  | 0.004426946|                           |
| PGK1      | 4.935                                | 3.02E−07  | 0.001669392|                           |
| G6PDH     | 4.816                                | 9.46E−06  | 0.04469885 |                           |
| ALDOA     | 4.151                                | 9.39E−07  | 0.005056988|                           |
| PGLS      | 3.153                                | 3.87E−06  | 0.019611519| pentose phosphate pathway   |
| TALDO1    | 5.062                                | 6.88E−08  | 0.000383949| fructose and mannose metabolism |
| PGLS      | 3.153                                | 3.87E−06  | 0.019611519|                           |
| TALDO1    | 5.062                                | 6.88E−08  | 0.000383949|                           |
| AKR1B7    | 4.035                                | 5.08E−07  | 0.002780961|                           |
| AKR1B1    | 6.11                                 | 1.58E−06  | 0.008361881|                           |
| UGP2      | 3.782                                | 7.14E−07  | 0.003872956|                           |
| GALK1     | 3.06                                 | 2.92E−07  | 0.001615368|                           |

Table 1. Change of proteins involved in glycometabolism pathways.
or 24 h. Then cells were washed three times with phosphate-buffered saline (PBS) and observed cell morphology by microscope.

**Quantification of viability cell number.** The number of cells were counted by cell counter under microscope (Nikon E200) after stained with trypan blue (Beyotime, C0011). Dead cells can be stained blue by Trypan blue due to ruptured membranes, while living cells are colorless. And the percentage of colorless cells (the number of colorless cells / the total number of cells) represents cell viability.

**Quantification of MNGCs.** RAW264.7 cells were cultured in 10 cm dish (5 × 10⁶) for 24 h and challenged them via the infected with MOI 50 of *B. pseudomallei* HNBP001 for 0, 1, 3, 6, 12, or 24 h. Then assessment of the percentage of MNGC formation via staining with Giemsa and counted with cell counter under a microscope (Nikon E200), uninfected cells were included as a control. All the living cells can be stained blue with Giemsa, and the number of nuclei can be observed under microscope. The total number of cells and the number of cells within MNGCs (binuclei, trinuclei, multinuclei) were counted with cell counter and examined at least 500 cells in each condition. The percentage of MNGC was calculated according to the following equation: \[\frac{\text{number of nuclei within MNGCs (binuclei, trinuclei, multinuclei)}}{\text{total number of nuclei}} \times 100\%\]. The same experiment performed three times independently.

**Plaque formation assay.** RAW264.7 cells were cultured in 10 cm dish (5 × 10⁶) for 24 h and challenged them via the infected with MOI 0, 0.5, 1, 10, 20, 50 of *B. pseudomallei* HNBP001 for 1, 3, 6, 12, or 24 h. Then plaque forming efficiency was calculated by the equation: the number of plaques (plaque-forming units: PFU) / the number of colony-forming units initially used for the infection, assessed by plating dilutions of the bacterial suspension. We defined plaques as defects in the monolayer resulting from MNGCs that have enlarged and are about to burst, as well as MNGCs that have already lysed⁹.

**Protein extraction and trypsin digestion.** RAW264.7 cells were cultured in 10 cm dish (5 × 10⁶) for 24 h and challenged them via the infected with MOI 50 of *B. pseudomallei* HNBP001 for 12 h. Then cells were washed with PBS and collected by centrifuging at 1000 × g for 5 min. The volume of 10% TCA/acetone was added to the cell sample for four times and left it at −20 °C, 4 h. The precipitate was washed three times with cold
acetone after centrifuging at 4500 × g for 5 min. The precipitate was lysed in 8 M Urea again, and the supernatant was collected as whole RAW246.7 cells extract. The protein concentration was determined by the BCA kit and digested samples (100 µg) at 4 °C overnight with trypsin in a ratio of 1:50 (trypsin: protein, m/m), then reduced with 5 mM dithiothreitol at 56 °C for 30 min.

The proteins of human serum samples (meliodosis and health controls) were extracted with the ProteoPrep Total Extraction Sample Kit (Merck), and the protein concentration was determined by the BCA kit. The sample (100 µg) was reduced with 5 mM dithiothreitol at 56 °C for 30 min and then used ultrafiltration with 8 M Urea. Then they were digested at 4 °C overnight with trypsin in a ratio of 1:50 (trypsin: protein, m/m).

**TMT labelling.** The tryptic peptides were separated in Strata×C18 (Phenomenex) and dissolved them with 0.5 M TEAB. Then the peptides were incubated with TMT in a ratio of 1:2 (peptides: TMT, μg/M) at room temperature for 3–5 h then dried them in a vacuum concentrator.

**LC–MS/MS analysis.** QE Plus mass spectrometer (Thermo Scientific Q Exactive Plus) was used for proteomic analysis. We graded the peptides by high pH reverse HPLC with Agilent 300 Extend C18 chromatographic column (particle size, 5 µm; inner size, 4.6 mm; length, 250 mm). The dried peptide samples were re-dissolved in Solvent A (0.1% formic acid and 2% acetonitrile in water) and loaded them to UHPLC for separation at a flow rate of 500 nL/min for 40 min with phase B (0.1% formic acid and 90% acetonitrile in water). During separation, the phase gradient was 0–20 min, 7–20% B; 20–33 min, 20–32% B; 33–37 min, 33–32% B; 37–40 min, 80% B. After separated by UHPLC, the peptides were loaded into an NSI ion source for ionization at 2.1 kV and analyzed by Q Exactive™ Plus mass spectrometry. The scan range of the mass spectrometry, scan resolution was 400–1500 m/z and 70,000, respectively. The start of the two-stage mass spectrometry, and the scan resolution was 100 m/z and 17,500, respectively.

To improve the effective utilization of MS, the automatic gain control (AGC) was set to 3E6. Additionally, the signal threshold was set to 7.8E4 ions/s, the maximum loaded time was 50 ms, and the dynamic exclusion time of tandem mass spectrometry was 30 s. Data were acquired using the data dependency scanner.

**Proteome data analysis.** The MS/MS data were processed using Maxquant search engine (v.1.5.2.8). Tandem mass spectra were searched against mouse or human Uniprot database concatenated with reverse decoy database. Trypsin/P was specified as cleavage enzyme allowing up to 4 missing cleavages. The mass tolerance for precursor ions was set as 20 ppm in First search and 5 ppm in Main search, and the mass tolerance for fragment ions was set as 0.02 Da. Carbamidomethyl on Cys was specified as fixed modification and acetylation modification and oxidation on Met were specified as variable modifications. FDR was adjusted to <1% and minimum score for modified peptides, was set > 40. Protein expressed profiles were normalized by log2-transformed, and the differentially expressed proteins were identified according to the Holm adjusted P < 0.05 in the student’s t-test and Fold Change ≥ 2 or ≤ 0.5 in which Fold Change values were calculated as the ratio of the mean protein expressed levels in Bp group to NC group. GO and KEGG enrichment analysis were performed and visualized by the R package “clusterProfiler” with the default cutoff threshold (Benjamini—Hochberg adjusted P < 0.05). We performed all statistical analyses using R software version 4.0.3 (http://www.r-project.org/).

**Western blot.** RAW246.7 cells (BP group and NC group) were lysed in SDS lysis buffer (1% SDS, 50 mM Tris–HCl, pH 7.5, 100 mM NaCl, and complete protease inhibitors (Roche)), measured the protein concentration with BCA kit, resolved 40 µg protein on a 4–12% SDS-PAGE gel, transferred it to a nitrocellulose membrane, and immunoblotted it with the indicated antibodies. The lanes containing the target sample are cropped and incubated with corresponding antibodies. We obtained the antibodies used in this study from the following sources: anti-PGM1 (2 µg/ml, Santa Cruz, sc-373796), anti-PGK1 (2 µg/ml, Santa Cruz, sc-130335), anti-PKM (2 µg/ml, Santa Cruz, sc-365684), anti-O-GlcNAc antibody (2 µg/ml, RL2, clone18B10.C7, Thermo Scientific), and anti-Actin (2 µg/ml, Beyotime, AA128).

**ATP measurement.** ATP content was measured using an ATP Assay Kit (Beyotime Institute of Biotechnology) according to the manufacturers’ instructions. In brief, RAW246.7 cells (BP group and NC group) were cultured in 96-well (1.5 ×104 per-well) for 24 h. Cells were lysed by lysis buffer supported in the kit, then lysis supernatant was collected and precipitation was discarded by centrifuging at 12,000 g, 4 °C for 5 min. Mix 20 µl supernatant with ATP detection reagent at room temperature for 3–5 min, then detected by Infinite 200 PRO Multimode Microplate Reader (-TECAN, Switzerland). The ATP level results were cell number normalized. Extra spaces with parentheses removed here and throughout.

**Glucose uptake assay.** The glucose uptake assay was performed according to the Glucose Uptake Assay Kit (Abcam, ab136955). RAW246.7 cells (BP group and NC group) were cultured in 96-well (2 ×103 per-well) for 24 h, and starved in serum free DMEM medium overnight. Cells were washed with PBS for 3times and pre-incubating with 100 µl 2%BSA buffer for 40 min at 37 °C. Then added 10 µl of 10 mM 2-DG (total in 100 µl PBS buffer) to cells, incubated for 20 min at 37 °C. Lysed cells with 80 µl extraction buffer by pipetting up and down. The cell lysates were freeze/thaw once, heated at 85 °C for 40 min and cooled on ice for 5 min. Added 10 µl neutralizing buffer to cells lysates. Then 10 µl reaction mix A and 40 µl cell lysates at 37 °C for 1 h, added 90 µl extraction buffer to each well and heat it at 90 °C for 40 min to degraded any unused NADP left. Added 38 µl reaction mix B to each well and mixed. Measured output at OD 412 nm on a microplate reader (Biotek) in a kinetic mode, every 2–3 min, at 37 °C.
Statistical analysis. The P-values were calculated from a student’s paired t-test when comparing within groups and from a student’s unpaired t-test when comparing between groups. For analyses where more than one t-test was applied to the same data set, statistical analyses were performed via a one-way analysis of variance and Dunnett test comparison post-test.

Data availability
All date generated analysed during this study are included in this published article and its supplementary information files.

Received: 23 February 2022; Accepted: 14 July 2022
Published online: 22 July 2022

References
1. Limmathurotsakul, D. et al. Activities of daily living associated with acquisition of melioidosis in northeast Thailand: A matched case-control study. PLoS Negl. Trop. Dis. 7(2), e2072 (2013).
2. Cheng, A. C. & Currie, B. J. Melioidosis: Epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18(2), 383–416 (2005).
3. Currie, B. J. Melioidosis: Evolving concepts in epidemiology, pathogenesis, and treatment. Semin. Respir. Crit. Care Med. 36(1), 111–125 (2015).
4. Wiersinga, W. J. et al. Melioidosis. Nat. Rev. Dis. Primers 4, 17107 (2018).
5. Tumapa, S. et al. Burkholderia pseudomallei genome plasticity associated with genomic island variation. BMC Genom. 9, 190 (2008).
6. Dong, S. et al. The prevalence and distribution of Burkholderia pseudomallei in rice paddy within Hainan, China. Acta Trop. 187, 165–168 (2018).
7. Fang, Y. et al. Melioidosis in Hainan, China: A retrospective study. Trans. R. Soc. Trop. Med. Hyg. 109(10), 636–642 (2015).
8. Zheng, X. et al. Endemic melioidosis in Southern China: Past and present. Trop. Med. Infect. Dis. 4(1), 44058 (2019).
9. Kuo, Y. et al. Whole-genome sequence of Burkholderia pseudomallei strain HNBp001, isolated from a melioidosis patient in Hainan, China. Microbiol. Resour. Announc. 8(36), 1140 (2019).
10. Zha, X. et al. Molecular characteristics of Burkholderia pseudomallei collected from humans in Hainan, China. Front. Microbiol. 11, 778 (2020).
11. Cruz-Migoni, A. et al. A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science 334(6057), 821–824 (2011).
12. Li, X. et al. O-GlcNacylation of core components of the translation initiation machinery regulates protein synthesis. Proc. Natl. Acad. Sci. U S A 116(16), 7857–7866 (2019).
13. Marriappa, V. et al. Hijacking of the Host’s Immune Surveillance Radars by Burkholderia pseudomallei. Front. Immunol. 12, 718719 (2021).
14. Schmidt, I. H. E. & Tumapa, S. Burkholderia pseudomallei modulates host iron homeostasis to facilitate iron availability and intracellular survival. PLoS Negl. Trop. Dis. 12(1), e006096 (2018).
15. Loaiza, C. D. et al. In silico prediction of host-pathogen protein interactions in melioidosis pathogen Burkholderia pseudomallei and human reveals novel virulence factors and their targets. Brief Bioinform. 22(3), 55689 (2021).
16. Fang, Y. et al. Burkholderia pseudomallei-derived miR-3473 enhances NF-kappaB via targeting TRAF3 and is associated with different inflammatory responses compared to Burkholderia thailandensis in murine macrophages. BMC Microbiol. 16(1), 283 (2016).
17. Tan, K. S. et al. Suppression of host innate immune response by Burkholderia pseudomallei through the virulence factor TssM. J. Immunol. 184(9), 5160–5171 (2010).
18. Peng, D. et al. Upregulation of immune process-associated genes in RAW264.7 macrophage cells in response to Burkholderia pseudomallei infection. Biomed. Res. Int. 2018, 1235097 (2018).
19. Xu, W. et al. Global profiling of crotonylation on non-histone proteins. Cell Res. 27(7), 946–949 (2017).
20. Martiapan, V., Vellasamy, K. M. & Vadivelu, J. Host-adaptation of Burkholderia pseudomallei alters metabolism and virulence: A global proteome analysis. Sci. Rep. 7(1), 9015 (2017).
21. Jordi, T. & Khams, H. Simple solution to a common statistical problem: Interpreting multiple tests. Clin. Ther. 26(5), 780–786 (2004).
22. Ge, S. et al. A proteomic landscape of diffuse-type gastric cancer. Nat. Commun. 9(1), 1012 (2018).
23. Xie, M. et al. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation. Nat. Commun. 7, 13280 (2016).
24. Zhang, Y. et al. Macrophage-associated PGK1 phosphorylation promotes aerobic glycolysis and tumorigenesis. Mol. Cell 71(2), 201–215, e7 (2018).
25. Li, Y. et al. AMPK-dependent phosphorylation of HDAC8 triggers PG1M expression to promote lung cancer cell survival under glucose starvation. Cancer Lett. 478, 82–92 (2020).
26. French, C. T. et al. Dissection of the Burkholderia intracellular life cycle using a photothermal nanoblade. Proc. Natl. Acad. Sci. U S A 108(29), 12095–12100 (2011).
27. Welkos, S. et al. A DUF4148 family protein produced inside RAW264.7 cells is a critical Burkholderia pseudomallei virulence factor. Virulence 11(1), 1041–1058 (2020).
28. Zhang, Y. et al. Activation of PGK1 under hypoxic conditions promotes glycolysis and increases stem celllike properties and the epithelialmesenchymal transition in oral squamous cell carcinoma cells via the AKT signalling pathway. Int. J. Oncol. 57(3), 743–755 (2020).
29. Dai, L. et al. High expression of ALDOA and DDX5 are associated with poor prognosis in human colorectal cancer. Cancer Manag. Res. 10, 1799–1806 (2018).
30. Fu, H. et al. Aldolase A promotes proliferation and G1/S transition via the EGFR/MAPK pathway in non-small cell lung cancer. Cancer Commun. (Lond) 38(11), 18 (2018).
31. Zhang, C. et al. C/D-box snord105b promotes tumorigenesis in gastric cancer via ALDOA-C-Myc pathway. Cell Physiol. Biochem. 45(6), 2471–2482 (2018).
32. Qi, W. et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat Med 23(6), 753–762 (2017).
33. Vander, H. M. G., Campbell, L. C. & Thompson, C. B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324(5930), 1029–33 (2009).
34. Mok, B. Y. et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature 583(7817), 631–637 (2020).
35. Anwar, M. et al. Bongkrekic acid—a review of a lesser-known mitochondrial toxin. J. Med. Toxicol. 13(2), 173–179 (2017).
36. Mariappan, V. et al. Adhesion and invasion attributes of Burkholderia pseudomallei are dependent on airway surface liquid and glucose concentrations in lung epithelial cells. Environ. Microbiol. Rep. 10(2), 217–225 (2018).
37. Kronsteiner, B. et al. Diabetes alters immune response patterns to acute melioidosis in humans. Eur. J. Immunol. 49(7), 1092–1106 (2019).
38. Jenjaroen, K. et al. T-cell responses are associated with survival in acute melioidosis patients. PLoS Negl. Trop. Dis. 9(10), e0004152 (2015).
39. Koh, G. C. et al. The impact of diabetes on the pathogenesis of sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 31(4), 379–388 (2012).
40. Rexach, J. E., Clark, P. M. & Hsieh-Wilson, L. C. Chemical approaches to understanding O-GlcNAc glycosylation in the brain. Nat. Chem. Biol. 4(2), 97–106 (2008).
41. Rao, X. et al. O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth. Nat. Commun. 6, 8468 (2015).
42. Ferrer, C. M. et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol. Cell 54(5), 820–831 (2014).
43. Akan, I. et al. Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration. J. Neurochem. 144(1), 7–34 (2018).
44. Akimoto, Y. et al. O-GlcNAc modification of nucleocytoplasmic proteins and diabetes. Med. Mol. Morphol. 38(2), 84–91 (2005).
45. Chang, Y. H., Weng, C. I. & Lin, K. I. O-GlcNAcylation and its role in the immune system. J. Biomed. Sci. 27(1), 57 (2020).
46. Mariappan, V. et al. Identification of immunogenic proteins from Burkholderia cepacia secretome using proteomic analysis. Vaccine 28(5), 1318–1324 (2010).
47. Bulterys, P. L. et al. An in situ high-throughput screen identifies inhibitors of intracellular Burkholderia pseudomallei with therapeutic efficacy. Proc. Natl. Acad. Sci. U S A 116(37), 18597–18606 (2019).

Acknowledgements
The authors wish to acknowledge Dr. Xinhua Yu, Professor of Research Center Borstel, Germany, for his help in advising the language and text layout of this paper.

Author contributions
X.L. and Q.X.: designed research and wrote the paper; Y.Z. and S.G.: performed research and analyzed data; C.C. and L.L.: contributed reagent/-analytic tools. All authors commented on previous versions of the manuscript, read and approved the final manuscript.

Funding
This work was supported by the Major Science and Technology Program of Hainan Province (ZDKJ202003), the National Science Foundation of China (Grants 82060001), the National Science Foundation of China (Grants 32000902), the Hainan Provincial National Science Foundation of China (Grant 820RC629), and the Young Talents’ Science and Technology Innovation Project of Hainan Association for Science and Technology (Grant QCXM202015). The serum samples were from the Second Affiliated Hospital of Hainan Medical University.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-16716-z.

Correspondence and requests for materials should be addressed to Q.X.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022